|
Johnson & Johnson so far has not reported any sales figures for Xarelto, but said in July that it was among several new products posting strong sales in the second quarter. The company markets Xarelto jointly with Bayer Healthcare. Xarelto competes with Boehringer Ingelheim's Pradaxa, which was approved for U.S. sales in late 2010. Both drugs are very pricey compared to warfarin, which typically costs well under $10 a month, plus $1,600 or more a year for frequent tests of its level in the blood. Pradaxa, taken twice a day, costs more than $260 per month. Xarelto, taken once a day, costs more than $250 per month. The two new pending uses for Xarelto call for two pills a day, at different dosages and likely a different price. The drugs' makers are striving to get more patients on those two drugs before the likely arrival of a third competitor that some analysts have said appears to work better: Eliquis. That drug, developed by partners Bristol-Myers Squibb Co. and Pfizer Inc., was rejected in June by the FDA. The agency is requiring additional information on Eliquis before it will again consider approval.
[Associated
Press;
Copyright 2012 The Associated
Press. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Community |
Perspectives
|
Law & Courts |
Leisure Time
|
Spiritual Life |
Health & Fitness |
Teen Scene
Calendar
|
Letters to the Editor